跳至主要内容
临床试验/NCT04721041
NCT04721041招募中不适用

Efficacy and Safety of Washed Microbiota Transplantation for the Treatment of Oncotherapy-Related Intestinal Complications

The Second Hospital of Nanjing Medical University1 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2021年1月26日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
200
试验地点
1
主要终点
Scores of gastrointestinal symptoms

研究概览

简要总结

Gut microbiota, known as "unrecognized organs", is closely related to the occurrence and development of tumors. Cancer is thought to occur secondary to local chronic inflammation. And some bacteria, such as Helicobacter pylori, also have direct genotoxicity, changing intracellular signaling pathways and thus causing abnormal cell growth. Systemic intestinal dysbiosis may lead to cancer, and fecal microbiota transplantation (FMT) can be a new weapon in anti-cancer treatment.Washed microbiota transplantation (WMT), a new stage of FMT, is based on the automatic microfiltration machine (GenFMTer, Nanjing, China) and the following repeated centrifugation plus suspension with support from specific facilities. The investigators conducted a prospective, one-arm, open-label study on the efficacy and safety of WMT in the treatment of oncotherapy-related complications. This study aimed to exploring the therapeutic potential of WMT in the treatment of oncotherapy-related intestinal complications and improving the quality of life of patients.

详细描述

Gut microbiota, known as "unrecognized organs", is closely related to the occurrence and development of tumors. Cancer is thought to occur secondary to local chronic inflammation. And some bacteria, such as Helicobacter pylori, also have direct genotoxicity, changing intracellular signaling pathways and thus causing abnormal cell growth. Systemic intestinal dysbiosis may lead to cancer, and fecal microbiota transplantation (FMT) can be a new weapon in anti-cancer treatment. The reduction of intestinal flora diversity may lead to intestinal dysbiosis, thereby reducing the body immunity and promoting the formation and development of neoplasm. It has been reported that FMT can be used to treat melanoma, liver cancer and prostate cancer after immunotherapy failed. But the mechanism of gut microbiota on the tumor itself remains to be further explored. In 2019, an Italian study reports the efficacy of FMT for diarrhea induced by tyrosine kinase inhibitors in the treatment of renal cell carcinoma, suggesting the therapeutic potential of gut microbiota for tumor-related gastrointestinal complications [1].

Fecal Microbiota transplantation (FMT), the most classic way to treat diseases using gut microbiota [2], refers to the transplantation of functional microbiota in the feces of healthy people into the intestines of patients. It can reconstruct the overall gut microbiota of patients, thus treating gastrointestinal diseases and external gastrointestinal diseases of patients. In 2013, FMT was for the first time coined into the treatment guidelines on recurrent CDI, and now it plays an important role as a key treatment for clostridium difficile infection [3]. Washed microbiota transplantation (WMT), a new stage of FMT, is based on the automatic microfiltration machine (GenFMTer, Nanjing, China) and the following repeated centrifugation plus suspension with support from specific facilities. Compared with manual FMT, WMT can reduce the rate of adverse events (such as fever, diarrhea, abdominal pain, abdominal distension, nausea and vomiting, etc.) without affecting the efficacy. In addition, Zhang et al. have proved that WMT is better than the manual preparation of FMT in improving safety, enriching the precise amount of microbiota and quality controllable in practice [4]. In December 2019, A panel of 28 experts from 22 hospitals or institutes in 15 cities has contributed to the "Nanjing consensus on methodology of washed microbiota transplantation" according to the international standards, and the consensus is published in Chinese Medical Journal in July 2020 [5].

Therefore, the investigators conducted a prospective, one-arm, open-label study on the efficacy and safety of WMT in the treatment of oncotherapy-related intestinal complications. This study aimed to exploring the therapeutic potential of WMT in the treatment of oncotherapy-related intestinal complications and improving the quality of life of patients.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 1. Age ≥18 years old;
  • Diagnosed as malignant tumor;
  • Patients who underwent cancer-related treatment suffering from gastrointestinal symptoms(e.g., abdominal pain, diarrhea, abdominal distension, and difficulty defecating) occurred after standard tumor therapy (such as chemotherapy, radiation, immunotherapy, surgical treatment, etc.);
  • Estimated time of survival ≥ 3 months, and vital signs were stable);
  • Physically qualified and intended to undergo FMT;

排除标准

  • 1. Patients who were pregnant or nursing;
  • Patients who were unable or unwilling to undergo a gastroscopy or colonoscopy;
  • Patients with cardiopulmonary failure;
  • Antibiotics, PPI, probiotics, and other drugs that alter gut microbiota were used in the previous week;
  • history of inflammatory bowel disease and intestinal symptoms unrelated to tumor treatment; 6.Serious uncontrolled diseases and acute infectious diseases;

研究组 & 干预措施

Basic treatment

No Intervention

Basic treatment based on the lastest clinical guidelines

Washed Microbiota Transplantation (WMT)

Experimental

Patients undergo once WMT a day for three consecutive days.

干预措施: Washed Microbiota Transplantation (WMT) (Other)

结局指标

主要结局

Scores of gastrointestinal symptoms

时间窗: 8 weeks

Gastrointestinal symptoms will be evaluated according to NCI-CTC 5.0

Stool frequency and consistency

时间窗: 8 weeks

Stool frequency and consistency will be evaluated according to The Bristol Stool Form Scale (BSFS).

次要结局

  • Adverse events(1 year)
  • Karnofsky Performance Status (KPS) scale(8 weeks)

研究者

发起方
The Second Hospital of Nanjing Medical University
申办方类型
Other
责任方
Principal Investigator
主要研究者

Faming Zhang

Professor, Gastroenterology

The Second Hospital of Nanjing Medical University

研究点 (1)

Loading locations...

相似试验